The Tanenbaum Centre for Pharmacogenetics was founded in 2011 through the generous support of Larry and Judy Tanenbaum. The Centre is primarily a research laboratory headed by, Dr James Kennedy, located at the College Street site of the Centre for Addiction and Mental Health (CAMH). The main goal of the Centre is to provide support for young investigators working in the field of psychiatric pharmacogenetics.
• Discovery of novel genetic and epigenetic variants involved in the response and development of side effects (eg. Tardive Dyskenesia) to psychiatric medications
• Design of a diagnostic psychiatric pharmacogenetic variant testing panel for patients who have been prescribed, or will be prescribed, antipsychotic and/or antidepressant medication
• Optimization of a high-throughput testing procedure for a genetic variant associated with treatment response to naltrexone, one of the only forms of pharmacotherapy for individuals being treated for alcohol dependence/abuse
• Determining the frequencies of known pharmacogenetic variants in two Ontario First Nations populations in collaboration with CAMH’s Social and Epidemiological Research Department
• Development of a computerized keyword search of electronic medical records to rapidly track the response and development of side effects in our study participants.
Resources and facilities
• ViiA™ 7 Real-Time PCR System
• QuantStudio™ 12K Flex System with OpenArray™ Block
• Chemagen MSMI automated DNA extractor
• Ion PGM™ System
• Ion Proton™ Sequencer
• SOLiD® 5500 Next-Generation Sequencer
• Specialized Computing Cluster
Lab Manager - Natalie Freeman MLT, MSc
Research Analysts - Maria Tampakeras (MSc), David Irwin (MSc), Sajid Shaikh (BScH), David Sibony (MSc)